Menu
Search
|

Menu

Close
X

Blueprint Medicines Corp BPMC.OQ (NASDAQ Stock Exchange Global Select Market)

84.08 USD
+0.08 (+0.10%)
As of 7:05 PM GMT
chart
Previous Close 84.00
Open 83.77
Volume 36,399
3m Avg Volume 134,329
Today’s High 84.52
Today’s Low 80.92
52 Week High 104.82
52 Week Low 45.15
Shares Outstanding (mil) 39.12
Market Capitalization (mil) 2,592.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
45
FY17
21
FY16
28
EPS (USD)
FY18
-5.393
FY17
-3.893
FY16
-2.633
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
101.33
8.39
Price to Book (MRQ)
vs sector
6.92
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.71
16.02
LT Debt to Equity (MRQ)
vs sector
0.18
11.35
Return on Investment (TTM)
vs sector
-34.88
13.82
Return on Equity (TTM)
vs sector
-40.89
15.25

EXECUTIVE LEADERSHIP

Daniel Lynch
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Jeffrey Albers
President, Chief Executive Officer, Director, Since 2014
Salary: $515,375.00
Bonus: --
Michael Landsittel
Chief Financial Officer, Since 2019
Salary: $260,936.00
Bonus: --
Kathryn Haviland
Chief Operating Officer, Since 2019
Salary: $353,451.00
Bonus: --
Tracey McCain
executive vice president and chief legal, Since 2016
Salary: $130,846.00
Bonus: $100,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

45 Sidney St
CAMBRIDGE   MA   02139-4133

Phone: +1617.3747580

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

SPONSORED STORIES